ATHE - Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy
- Alterity Therapeutics ( NASDAQ: ATHE ) said the first patient was dosed in a a phase 2 trial of ATH434 in Multiple System Atrophy (MSA)
- MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect breathing, digestion and bladder control.
- The trial is expected to enroll ~60 adult patients who will either receive one of two doses of ATH434 or placebo for one year.
For further details see:
Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy